New and experimental HIV treatments: latest news

New and experimental HIV treatments features

New and experimental HIV treatments in your own words

New and experimental HIV treatments news from aidsmap

More news

New and experimental HIV treatments news selected from other sources

  • GSK touts new Dovato switching data. Is it enough to shake Gilead's HIV lead?

    GlaxoSmithKline’s ViiV Healthcare already boasts an approval for Dovato, a two-drug HIV regimen, in newly diagnosed patients. And it just added some new data that aims to at least draw level with market leader Gilead in already-treated patients.

    11 July 2019 | FiercePharma
  • ViiV Healthcare receives EU marketing authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection

    Authorisation based on GEMINI pivotal trials in which Dovato achieved non-inferior efficacy compared to a dolutegravir-based, three-drug regimen through 48 weeks, with no cases of resistance.

    03 July 2019 | ViiV press release
  • 1 Year After Approval: How Does D/C/F/TAF Measure Up?

    The US Food and Drug Administration (FDA) approved the first darunavir-based single-tablet regimen (STR) for the treatment of HIV in July 2018. Now, nearly a year since its launch, health care practitioners and patients alike are evaluating its place in the HIV treatment landscape.

    01 July 2019 | Contagion Live
  • Novel HIV-1 Inhibitor Shows Promise for Future Treatment of HIV in Women

    Avirulins may provide a valuable chemical foundation for the development of the next generation of prophylactic medications for HIV-1 in women, according to results of a study presented at American Society of Microbiology (ASM) Microbe 2019 held from June 20-24, 2019, in San Francisco, California.

    26 June 2019 | Infectious Disease Advisor
  • Major HIV drug calls for vigilance

    A study lead by researchers at the Institute of HIV Research, Medical Faculty of UDE and University Hospital Essen, stumbled over a potential toxicity of integrase inhibitors. The researchers found that INSTI had a dramatic effect on activity of immune cells and in particular reduced the activity and function of CD4 T helper cells. This included a reduced proliferation and multiplication of these cells.

    24 June 2019 | University of Duisberg-Essen
  • Biktarvy Approved to Treat Pediatric Patients With HIV-1

    he Food and Drug Administration (FDA) has approved updated labeling for Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide; Gilead) to include treatment of both adult and pediatric patients weighing at least 25kg with HIV-1 who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy. Previously, the combination therapy had only been approved for adults.

    20 June 2019 | Monthly Prescribing Reference
  • CytoDyn Announces Major Discovery for its Monotherapy Indication

    CytoDyn, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today significant progress in securing the therapeutic effect and safety of leronlimab (PRO 140) with the development of an assay that can reliably determine a patient’s CCR5 status.

    20 June 2019 | CytoDyn press release
  • CytoDyn: Uncovering An Opportunity

    CytoDyn is moving their PRO 140 product candidate closer towards an FDA approval in HIV.

    12 June 2019 | Seeking Alpha
  • Could gold be the key to making gene therapy for HIV, blood disorders more accessible?

    Could gold be the key to making gene therapy for HIV, blood disorders more accessible?  Scientists at Fred Hutchinson Cancer Research Center took a step toward making gene therapy more practical by simplifying the way gene-editing instructions are delivered to cells. Using a gold nanoparticle instead of an inactivated virus, they safely delivered gene-editing tools in lab models of HIV and inherited blood disorders, as reported May 27 in Nature Materials.

    28 May 2019 |
  • CytoDyn Files Pivotal Trial Protocol for HIV Monotherapy with FDA

    After four years of monotherapy trials, data is now available to submit the long-anticipated pivotal trial for monotherapy to the FDA. Trial will include 10 weeks of induction therapy to identify which patients are likely to respond and which patients can safely return to their original HAART regimen.

    17 May 2019 | CytoDyn press release
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.